More Cambium Bio Ltd news
Cambium Bio LtdASX: CMB

US Patent Office to allow key patent for Progenza

Jul 9, 2018 at 11:22 PM EDT · Issued by Cambium Bio Ltd

Filed with ASX · Jul 9, 2018 at 11:22 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/us-patent-office-to-allow-key-patent-for-progenza

Cambium Bio Ltd on 6ix

Story so far

  • Update on licensing Progenza in JapanJul 3, 2018
  • European Medicines Agency grants Progenza ATMP statusFeb 14, 2018
  • Japanese Patent Office to grant patent for cancer vaccineFeb 12, 2018

Earlier from Cambium Bio

  • Update on licensing Progenza in JapanJul 3, 2018
  • European Medicines Agency grants Progenza ATMP statusFeb 13, 2018
  • Japanese Patent Office to grant patent for cancer vaccineFeb 11, 2018
  • Regeneus Announces Successful Results in Acne StudyFeb 6, 2018
  • CEO Presentation to 2017 Annual General MeetingNov 2, 2017

Later from Cambium Bio

  • Positive clinical trial results for cancer vaccineJul 30, 2018
  • Regeneus receives R&D tax incentive refund of $2.4mSep 5, 2018
  • Progenza patent to grant in EuropeOct 17, 2018
  • Re-Released - Appendix 4C - QuarterlyOct 23, 2018
  • Chinese patent granted for biomarkers for stem cell therapyDec 2, 2018
All Cambium Bio news releases↗

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer